AkzoNobel


Less expensive than feared…

10/01/22 -"… but still somewhat costly. Akzo is guiding for the upper end of the €310-340m higher cost range yoy. We had felt this might be a notch above the upper end. Sales price increases are seen at 12-14%. ..."

Pages
51
Language
English
Published on
10/01/22
You may also be interested by these reports :
24/01/22
We have lifted our 2021 and 2022 estimates after speaking with the company. It does not see any inventory building in automotive, which is good for ...

13/01/22
We have taken the positive effect from Yara’s decision into account as we now expect a somewhat higher ASP in 2022 and a more moderate decline in ...

10/01/22
… but still somewhat costly. Akzo is guiding for the upper end of the €310-340m higher cost range yoy. We had felt this might be a notch above the ...

05/01/22
… pushes per-share-based valuations. We have taken BASF’s re-vitalised share buy-back ambitions into account. The company plans to purchase own ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO